Research

Clinical Trial Summaries

1. Belatacept 027 - Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
   Sponsor: Bristal Myers
2. Belatacept 008 - Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial
   Sponsor: Bristal Myers
3. RAD 2401 - A facilitated access program to provide Everolimus (RAD) for maintenance patients completing therapy in RAD trials in solid organ transplantation
   Sponsor: Novartis Pharmaceuticals
4. CTOT-01 - Noninvasive Monitoring to Predict Outcome in De Novo Kidney Transplant Recipients Sponsor: National Institute of Health
5. Sirolimus 316 - A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients.
   Sponsor: Wyeth Pharmaceuticals
6. A3921030 - A Phase 2 Randomized, Multi-center, Active Comparator-Controlled Trial To Evaluate The Safety And Efficacy Of Co-administration Of CP-690,550 And Mycophenolate Mofetil / Mycophenolate Sodium In De Novo Kidney Allograft Recipients.
   Sponsor: Pfizer, Inc
7. Mygain - A 4-week, multicenter, double-blind, randomized, parallel group study to compare the gastrointestinal (GI) safety and tolerability of myfortic® and MMF (Cellcept®)when administered in combination with calcineurin inhibitors (CNI) in renal transplant recipients experiencing gastrointestinal intolerance
   Sponsor: Novartis Pharmaceuticals